Bortezomib Combination Therapy in Multiple Myeloma
Author:
Publisher
Elsevier BV
Subject
Hematology
Reference69 articles.
1. Proteasome inhibition as a novel therapeutic target in human cancer;Rajkumar;J Clin Oncol,2005
2. A phase 2 study of bortezomib in relapsed, refractory myeloma;Richardson;N Engl J Med,2003
3. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study;Kumar;Leukemia,2012
4. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies;Orlowski;J Clin Oncol,2002
5. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial;Richardson;Cancer,2006
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells;Heliyon;2024-06
2. Identification and validation of a platelet-related signature for predicting survival and drug sensitivity in multiple myeloma;Frontiers in Pharmacology;2024-05-16
3. Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma;Transfusion and Apheresis Science;2023-06
4. Histone deacetylase‐based dual targeted inhibition in multiple myeloma;Medicinal Research Reviews;2023-05-16
5. Investigating the complexation propensity of self-assembling dipeptides with the anticancer peptide-drug Bortezomib: a computational study;Soft Matter;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3